Evidence map›Paper›PMID 40766828›Full record

ArticleBlood vessels, thrombosis & hemostasis2024

Real-world insights on the management of immune-mediated thrombotic thrombocytopenic purpura with caplacizumab.

Daan Dierickx, Thierry Connerotte, Julie Dallemagne, Ann De Becker, Ine Moors, Sylvia Snauwaert, Anne Sonet, Koen Theunissen, Dimitri Breems, Adrien De Voeght and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood vessels, thrombosis & hemostasis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Daan DierickxDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
Thierry ConnerotteOncology-Hematology Unit, Clinique Saint Pierre, Ottignies, Belgium.
Julie DallemagneHematology Department, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
Ann De BeckerDepartment of Hematology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Ine MoorsUniversity Hospital Ghent, Ghent, Belgium.
Sylvia SnauwaertDepartment of Hematology, AZ Sint-Jan, Bruges, Belgium.
Anne SonetCHU UCL Namur Site Godinne, Yvoir, Belgium.
Koen TheunissenDepartment Hematology, Jessa Hospital, Hasselt, Belgium.
Dimitri BreemsDepartment of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium.
Adrien De VoeghtDepartment of Clinical Hematology, Centre Hospitalier Universitaire de Liège, Liège, Belgium.
Aurélie JaspersDepartment of Hematology, CHR Citadelle, Liège, Belgium.
Catherine LambertDepartment of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Bert HeyrmanDepartment of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium.
Joris HautekietIQVIA Belux, Zaventem, Belgium.
Sofie LynaSanofi, Diegem, Belgium.
Chantal MaertensSanofi, Diegem, Belgium.
Vanessa DelrieuDepartment of Hematology, Hôpital de Jolimont, La Louvière, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40766828
PMCPMC12320383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.